Ian Flinn, MD, PhD, attended the Johns Hopkins University School of Medicine, Baltimore, MD, before completing residency training at the University of Michigan Medical Center, Ann Arbor, MI, and a Hematology and Medical Oncology fellowship at Johns Hopkins. He currently practices as a Hematologist/Oncologist at the Tennessee Oncology Center for Blood Cancers, Nashville, TN, and is Director of Lymphoma Research at the Sarah Cannon Research Institute, Nashville, TN. Dr Flinn is a member of the CLL Research Consortium, the American Society of Clinical Oncology and the American Society of Hematology.
Speaking on the development of novel therapies in CLL and lymphoma
Dr Flinn is an esteemed expert in hematological malignancies with an extensive publication record. His work focuses on developing new therapies in lymphoma and chronic lymphocytic leukemia (CLL). He has been involved in numerous clinical trials and is a Principal Investigator at the Sarah Cannon Research Institute. With new immunologic, chemotherapeutic and transplant approaches, he hopes to improve the outlook for these patient groups.